<DOC>
	<DOC>NCT02599688</DOC>
	<brief_summary>This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.</brief_summary>
	<brief_title>Open Label Extension of LipoLat-CS202</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<criteria>Inclusion criteria 1. Successful completion of 3 months of participation in Study LipoLatCS202. 2. Treatment with POLAT001 in Study LipoLatCS202. 3. Able and willing to give signed informed consent and follow study instructions. Exclusion criteria Excluded from the study will be individuals with the following characteristics: 1. The development, during study LipoLatCS202, of any exclusion criteria from that study (e.g., concomitant medication or comorbid disease).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>